Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
Palvella presented three posters at the Fall Clinical Dermatology Conference highlighting QTORIN rapamycin data in microcystic lymphatic malformations and a new DSAP epidemiology analysis. Phase 3 SELVA qualitative data showed 95% of participants improved on the primary mLM-IGA endpoint, 98% elected to continue treatment, and the maximal-use PK substudy found systemic rapamycin exposure at least 40-fold lower than oral sirolimus. A Komodo Health claims analysis estimated 154,986 diagnosed DSAP patients in the U.S. during 2018-2025, supporting the market opportunity for QTORIN pitavastatin, whose Phase 2 trial is expected to start in Q4 2026.
Key figures
- Drug Name
- QTORIN rapamycin (sirolimus topical gel 3.9%)
- Phase Of Trial
- Phase 3
- M LM IGA improvement
- 95%
- Pk exposure vs oral
- at least 40-fold lower
- Pk substudy participants
- 24
- Much or very much improved
- 86%
- Us dsap patients estimated
- 154986
- Continued treatment extension
- 98%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.